Abstract
In this review article we have reported a series of hybrid compounds characterized by the presence of a alpha-halogenocryloyl alkylating moiety of low chemical reactivity, linked to known antitumor agents or their active moieties. Among them, brostallicin (PNU-166196), was selected for clinical development and is now undergoing Phase II studies in patients with advanced or metastatic soft tissue sarcoma.
MeSH terms
-
Animals
-
Antineoplastic Agents, Alkylating / chemistry*
-
Antineoplastic Agents, Alkylating / pharmacology
-
Cell Line, Tumor
-
Distamycins / chemistry
-
Distamycins / pharmacology
-
Guanidines / chemistry
-
Guanidines / therapeutic use
-
Humans
-
Mice
-
Pyrroles / chemistry
-
Pyrroles / therapeutic use
-
Pyrroloiminoquinones / chemistry*
-
Pyrroloiminoquinones / pharmacology
Substances
-
Antineoplastic Agents, Alkylating
-
Distamycins
-
Guanidines
-
Pyrroles
-
Pyrroloiminoquinones
-
stallimycin
-
brostallicin